Bio Path Holdings Inc (BPTH)

[Snug9]

SJ, you are correct about reporting as related to the FDA. There is no requirement and to say the "FDA protocol" doesn't allow them to report the status of on-going studies is, in the current way of saying it, "fake news". The FDA may get involved if a company is reporting results that have not been verified or approved. They may issue a warning to the company or even a cease-and-desist order but all you have to do is look at the currently "successful" biopharms and you will see that they are keeping their investors updated without making forward-looking claims regarding their studies. Some of them are even issuing updates that their clinicals are not going well, e.g., Juno Pharm.. and Puma Bio... whose shares are still trading $25 to $90. What you are seeing from BioPath is smoke and mirrors which as we all can see is not impressing the market.